Search results for "Pharmacokinetic"

showing 10 items of 474 documents

Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in …

2009

Plasma levels of prolactin (PRL) and the butyrophenone neuroleptic benperidol (BPD) were closely followed 0 to 48 h after acute application of 6 mg BPD as intravenous injection, orally as liquid, and orally as tablets in 12 schizophrenic patients using a partially randomized cross over design. Drug concentrations showed application specific pharmacokinetic behavior with complete elimination within 48 h. All three applications led to a biphasic PRL response with pronounced initial plasma PRL peaks returning to baseline levels within 48 h. The results suggest that after acute neuroleptic challenge BPD plasma levels as low as 2-3 ng/ml can be sufficient for complete depletion of pituitary PRL …

AdultMaleendocrine systemmedicine.medical_specialtyEndocrinology Diabetes and MetabolismAdministration OralPharmacologyBenperidolchemistry.chemical_compoundEndocrinologyPharmacokineticsOral administrationInternal medicinemental disordersInternal MedicinemedicineHumansCross-Over Studiesbusiness.industryBenperidolHomovanillic acidDopaminergicAntagonistHomovanillic AcidGeneral MedicineProlactinProlactinEndocrinologychemistryInjections IntravenousSchizophreniaFemalebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugHormoneExperimental and Clinical Endocrinology & Diabetes
researchProduct

High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.

2015

Naringin is considered the major causative ingredient of the inhibition of intestinal drug uptake by grapefruit juice. Moreover, it is contained in highly dosed nutraceuticals available on the market. A controlled, open, randomized, crossover study was performed in 10 healthy volunteers to investigate the effect of high-dose naringin on the bioavailability of talinolol, a substrate of intestinal organic anion-transporting polypeptide (OATP)-mediated uptake. Following 6-day supplementation with 3 capsules of 350 mg naringin daily, 100mg talinolol were administered orally with 3 capsules of the same dietary supplement (1050 mg naringin) on the seventh day. This test treatment was compared to …

AdultMalefood.ingredientAdrenergic beta-AntagonistsPharmaceutical ScienceOrganic Anion TransportersPharmacologyPolymorphism Single NucleotideDosage formGrapefruit juicePropanolamineschemistry.chemical_compoundFood-Drug InteractionsYoung AdultNutraceuticalfoodPharmacokineticsHumansNaringinDosage FormsCross-Over StudiesDose-Response Relationship DrugChemistryCrossover studyBioavailabilityDietary SupplementsFlavanonesFemaleTalinololCitrus paradisiEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies.

1976

The pharmacodynamics and pharmacokinetics of the optical enantiomers of phenprocoumon were studied in 5 normal subjects and compared to the racemic mixture. Each subject received a single oral dose of 0.6 mg/kg of racemic, S(-), and R(+) phenprocoumon. S(-) phenprocoumon was 1.6 to 2.6 times as a potent as R(+) phenprocoumon when the area under the effect/time curve was used to quantify the total anticoagulant effect per dose. Comparing the plasma concentrations that elicited the same anticoagulant effect, S(-) phenprocoumon was 1.5 to 2.5 times as potent as R(+) phenprocoumon. The anticoagulant activity of the racemic mixture was between that of the enantiomers. There was no distinct diffe…

AdultMalemedicine.drug_classMetabolic Clearance RateIn Vitro TechniquesPhenprocoumonStructure-Activity RelationshipPharmacokineticsCoumarinsmedicineHumansPharmacology (medical)Serum AlbuminPharmacologyVolume of distributionChromatographyChemistryAnticoagulantAnticoagulantsStereoisomerismHuman serum albuminKineticsPharmacodynamicsPhenprocoumonProthrombin TimeRacemic mixtureEnantiomermedicine.drugProtein BindingClinical pharmacology and therapeutics
researchProduct

Bilateral ureteral obstruction and renal failure caused by massive retroperitoneal hematoma: is there a pelvic compartment syndrome analogous to abdo…

1998

Objectives: To describe an intrapelvic compartment syndrome analogous to abdominal compartment syndrome and to characterize its diagnosis and treatment. Design: Retrospective analysis. Setting: Level I trauma center. Patients: Three patients with pelvic ring or acetabular fractures presented with bilateral ureteral obstruction, renal organ failure. and anuria due to direct compression of both ureters in the true pelvis by a massive retroperitoneal hematoma, Intervention: Surgical therapy consisted of fracture stabilization, decompression of the retroperitoneal space, and evacuation of the hematoma. Persistent isolated bleeding points were either embolized preoperatively or ligated. Results:…

AdultMalemedicine.medical_specialtyAbdominal compartment syndromeDecompressionUrologyurologic and male genital diseasesCompartment SyndromesRetroperitoneal hematomaFractures BoneUreterHematomaMedicineRetroperitoneal spaceHumansOrthopedics and Sports MedicinePelvic compartmentRetroperitoneal SpaceCompartment (pharmacokinetics)Pelvic BonesHematomabusiness.industryAcetabulumGeneral MedicineAcute Kidney InjuryMiddle Agedmedicine.diseaseSurgeryRadiographysurgical procedures operativemedicine.anatomical_structureSurgeryAnuriaFemaleRadiologymedicine.symptombusinessKidney diseaseUreteral ObstructionJournal of orthopaedic trauma
researchProduct

Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

2018

Introduction: Personalised pharmacokinetics (PK) using Bayesian analysis with limited sampling is assumed to help to optimise prophylaxis in haemophilia A (HA) patients. Materials and methods: Our prospective, observational study analysed the influence of PK parameters on clinical variables (bleeding rates, joint status, adherence, and consumption) using myPKFiT (R) in a cohort of twenty-one severe and moderate HA patients on prophylaxis with recombinant FVIII (Advate (R)) in two periods of one year, the first before PK-based tailoring and the second after PK-guided prophylaxis. Intra-individual and inter-individual coefficients of variation (CV) of half-life (t(1/2)) were calculated. Resul…

AdultMalemedicine.medical_specialtyAdolescentHaemophilia AModerate haemophilia A030204 cardiovascular system & hematologyHemophilia ARecombinant factor viiiRecombinant factor VIIIYoung Adult03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineHaemophilia AArthropathymedicineLimited samplingHumansPharmacokineticsProspective StudiesAgedFactor VIIIbusiness.industryBayes TheoremHematologyBayesian estimationMiddle Agedmedicine.diseasePK-guided prophylaxis030220 oncology & carcinogenesisCohortFemaleObservational studybusinessmyPKFiTThrombosis Research
researchProduct

Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series

2020

BAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of nine patients affected by hemophilia A (HA), with variable disease severity, bleeding phenotype and comorbidities, to underline our clinical practice on prophylaxis with a recently introduced standard hall-life recombinant Factor VIII. The current case series highlights how the current clinical management of hemophilia is able to personalize treatment in several specific conditions like concomitant illnesses with thrombotic ris…

AdultMalemedicine.medical_specialtyAdolescentHemophilia A HemarthrosisHemophilic arthropathyrFVIIIPharmacokineticProphylaxisHaemophilia A030204 cardiovascular system & hematologyHemophilia ARecombinant factor viii03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicineHumansChildVariable disease severityAgedRetrospective StudiesThrombotic riskFactor VIIIbusiness.industryHematologyHemarthrosisMiddle Agedmedicine.diseaseThird generationClinical PracticeTreatment OutcomeConcomitantbusiness030215 immunology
researchProduct

The Effect of Age, Sex, Smoking and Co-Medication on Serum Levels of Venlafaxine and O-Desmethylvenlafaxine under Naturalistic Conditions

2012

Venlafaxine (VEN) is a modern antidepressant which exerts both serotonin and norepinephrine reuptake inhibition. In this study we examined the influence of age, sex, smoking, and co-medication on serum levels of VEN and its metabolite O-desmethylvenlafaxine (ODVEN) in patients treated with VEN under naturalistic conditions.We retrospectively evaluated 478 TDM analyses of VEN requested in the Pychiatric University Hospitals of Mainz, Regensburg, and Würzburg. The determination of serum levels was performed by virtually identical chromatographic methods in the TDM laboratories of the participating hospitals.Serum levels varied widely on each dose level. Women had about 30% higher dose-correct…

AdultMalemedicine.medical_specialtyAdolescentVenlafaxine HydrochlorideVenlafaxinePharmacokineticsDesvenlafaxine SuccinateInternal medicinemedicineHumansPharmacology (medical)DosingAgedRetrospective StudiesAged 80 and overSex Characteristicsbusiness.industrySmokingAge FactorsVenlafaxine HydrochlorideRetrospective cohort studyGeneral MedicineMiddle AgedCyclohexanolsPsychiatry and Mental healthAnesthesiaVenAntidepressive Agents Second-GenerationAntidepressantDrug Therapy CombinationFemaleDrug Monitoringbusinessmedicine.drugSex characteristicsPharmacopsychiatry
researchProduct

Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dos…

2015

ABSTRACT Isavuconazole is a novel broad-spectrum triazole antifungal agent. This open-label dose escalation study assessed the safety and pharmacokinetics of intravenous isavuconazole prophylaxis in patients with acute myeloid leukemia who had undergone chemotherapy and had preexisting/expected neutropenia. Twenty-four patients were enrolled, and 20 patients completed the study. The patients in the low-dose cohort ( n = 11) received isavuconazole loading doses on day 1 (400/200/200 mg, 6 h apart) and day 2 (200/200 mg, 12 h apart), followed by once-daily maintenance dosing (200 mg) on days 3 to 28. The loading and maintenance doses were doubled in the high-dose cohort ( n = 12). The mean ± …

AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaPyridinesClinical TherapeuticsNeutropeniaCohort StudiesPharmacokineticsInternal medicineNitrilesHumansMedicinePharmacology (medical)DosingAdverse effectAgedImmunosuppression TherapyPharmacologyDose-Response Relationship Drugbusiness.industryMiddle AgedTriazolesmedicine.diseaseIsavuconazoniumSurgeryLeukemia Myeloid AcuteInfectious DiseasesMycosesTolerabilityCohortFemalePatient Safetybusinessmedicine.drugCohort studyAntimicrobial Agents and Chemotherapy
researchProduct

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.

2006

SUMMARY Background: Venlafaxine (V) is a mixed serotoninand noradrenaline reuptake inhibitor used as afirst-line treatment of depressive disorders. It ismetabolized primarily by the highly polymorphiccytochrome P450 (CYP) enzyme CYP2D6 to yielda pharmacologically active metabolite, O-des-methylvenlafaxine (ODV), and to a lesser extentby CYP3A4, to yield N-desmethylvenlafaxine(NDV).Objectives: The aim of this study was to assesswhether the O-demethylation phenotype of V hasan impact on the pharmacokinetics and clinicaloutcome.Method: In 100 patients treated with V, serumconcentrations of V, ODV and NDV and theratios of concentrations ODV/V as a measure ofO-demethylation were determined. Indiv…

AdultMalemedicine.medical_specialtyCYP2D6AdolescentGenotypeVenlafaxine HydrochlorideVenlafaxineBiology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineDesvenlafaxine SuccinateGenotypemedicineHumansPharmacology (medical)Active metaboliteAgedPharmacologyDepressive DisorderPolymorphism GeneticfungiVenlafaxine HydrochlorideMiddle AgedCyclohexanols3. Good healthEndocrinologyCytochrome P-450 CYP2D6PharmacogeneticsAntidepressive Agents Second-GenerationFemaleReuptake inhibitor030217 neurology & neurosurgeryPharmacogeneticsmedicine.drugJournal of clinical pharmacy and therapeutics
researchProduct

Ocular Penetration of Topically Applied Norfloxacin 0.3% in the Rabbits and in Humans

1992

The kinetics of topically applied norfloxacin 0.3 percent were studied in rabbit and man. All measurements were performed by high-pressure liquid chromatography. Norfloxacin concentrations were investigated five to 120 minutes in rabbit ocular tissues after instillation of a single drop. In normal eyes, after 30 minutes, mean +/- SEM levels were 14.3 +/- 3.7 micrograms/g in cornea, 3.3 +/- 0.7 micrograms/g in conjunctiva, 0.2 +/- 0.1 microgram/g in aqueous humor. After removal of the corneal epithelium concentrations were as follows: 84.2 +/- 15.8 micrograms/g, 7.3 +/- 2.3 micrograms/g, 8.6 +/- 1.9 micrograms/g respectively. Penetration in posterior ocular tissues were rather poor. In human…

AdultMalemedicine.medical_specialtyConjunctivaAdolescentgenetic structures[SDV]Life Sciences [q-bio]EyeCorneaPharmacokineticsCorneaOphthalmologymedicineAnimalsHumansTissue DistributionPharmacology (medical)Chromatography High Pressure LiquidNorfloxacinAgedAntibacterial agentCorneal epitheliumAged 80 and overPharmacologyLagomorphabiologybusiness.industryPenetration (firestop)Middle Agedbiology.organism_classificationeye diseasesSurgeryOphthalmologymedicine.anatomical_structureFemaleRabbitssense organsOphthalmic SolutionsbusinessKeratoplasty PenetratingNorfloxacinmedicine.drugJournal of Ocular Pharmacology and Therapeutics
researchProduct